icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
 
 
  Reported by Jules Levin
EASL 2018 April 14 Paris France
Oral Late Breaker
 
Anna S. Lok,1 Ira Willner,2 K. Rajender Reddy,3 Mohamed A. Hassan,4 Federico Hinestrosa,5 Mitchell L. Shiffman,6 Mark S. Sulkowski,7 Ira M. Jacobson,8 Robert S. Brown Jr,9 Giuseppe Morelli,10 Joy Peter,10 Michael W. Fried,11 Monika Vainorius,11 Larry Michael,11 Gary P. Wang,10 Bonnie Yiran Hu,12 Jens Kort,12 David R. Nelson,10

0416181

0416182

0416183

0416184

0416185

0416186